Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesBariatric & Obesity ManagementVentura County Weight Loss Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedVentura County Health Care PlanPolicy 066

    GLP-1 Medications for Weight Loss Policy

    Customize your policy alerts

    Sign up for venturacountyhealthcareplan Policy 066 alerts

    Get alerted when Policy 066 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical-necessity, prior-authorization, and step-therapy requirements for anti-obesity medications prescribed for chronic weight management in members with severe or Class III obesity as part of a provider-supervised comprehensive weight management program.

    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGLP-1 Medications for Weight Loss Policy
    Policy CodePolicy 066
    Change TypeNew policy replacing the prior Weight Reduction Medications and Programs policy
    Effective DateDecember 20, 2026
    Next Review DateN/A
    Key ActionBefore requesting Zepbound, document that the member has tried Wegovy injection or Wegovy tablets and meets applicable prior-authorization criteria.
    SourceLink
    POLICY UPDATE CHANGES

    This is a new policy replacing the prior Weight Reduction Medications and Programs policy.

    6 monthsInitial authorization period
    6 monthsContinuation authorization period
    BMI ≥40Severe obesity threshold
    35–39BMI threshold with comorbidity

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Step 1 → Step 2Required product sequence
    ≥50%Weight regain threshold

    Medical Necessity and Coverage Criteria

    Initial Authorization

    Initial authorization may be approved for six (6) months when ALL of the following criteria are met:

    ALL of the following

    • The member meets the eligibility and medical-necessity criteria established in this policy, consistent with the member's Evidence of Coverage, applicable California law, FDA-approved labeling, and generally accepted standards of care. Coverage of weight loss medication must include treatment of Class III or severe obesity, defined as a BMI of 40 or higher, or a BMI of 35–39 paired with one or more obesity-related comorbidities.
    • Medication is prescribed for chronic weight management.
    • The member participates in a provider-supervised Comprehensive Weight Management Program.
    • A completed Prescription Drug Prior Authorization Request Form for Weight Loss Medication is submitted, including the member's weight and height measurements obtained and documented by a healthcare professional during an in-person physical examination.

    Continuation Authorization

    Continuation may be approved for an additional six (6) months when ALL of the following criteria are met:

    ALL of the following

    • Continued Medical Necessity is demonstrated, including continued clinical benefit, clinical appropriateness, tolerability, adherence, continued participation in a comprehensive weight management program, and an expectation of ongoing therapeutic benefit.
    • Medication continues to be well tolerated.
    • The member continues participation in a Comprehensive Weight Management Program.
    • The member demonstrates medication adherence.
    • ONE of the following

    Non-Covered Medication Uses

    Coverage is not provided when anti-obesity medications are prescribed solely for any of the following:

    ANY of the following

    • Cosmetic weight loss.
    • Appearance enhancement.
    • Athletic performance.
    • Members who do not satisfy medical-necessity criteria.
    • Any indication excluded under the member's Evidence of Coverage.

    Non-Covered Services

    The following services and supplies are not covered for weight reduction:

    ANY of the following

    • Rice or other special diet supplements or substitutes, including amino acid supplements, Optifast liquid protein meals, or NutriSystem pre-packaged foods.
    • Human chorionic gonadotropin (HCG) or vitamin injections for weight loss.
    • Acupuncture for weight loss.
    • Hospital confinements for a weight reduction program.
    • Exercise programs or use of exercise equipment.

    Coverage is excluded when anti-obesity medications are prescribed solely for cosmetic weight loss, appearance enhancement, or athletic performance.

    Anti-obesity medication use is not covered for members who do not satisfy the medical-necessity criteria or for any indication excluded under the member's Evidence of Coverage.

    Weight-reduction services and supplies that are not covered include diet supplements or substitutes, HCG or vitamin injections, acupuncture, hospital confinements for a weight-reduction program, exercise programs or equipment, commercial diet programs, whole body calorimetry, and other related devices, products, and services.

    Anti-obesity medication is not medically necessary when the member does not meet the eligibility and medical-necessity requirements established by this policy, the member's Evidence of Coverage, applicable law, FDA-approved labeling, and generally accepted standards of care.

    Requests for anti-obesity medication are not covered when the applicable medical-necessity criteria are not met.

    Clinical Thresholds and Review Triggers

    Severe or Class III obesity
    BMI 40 or higherQualifies as severe or Class III obesity.
    BMI 35–39Qualifies when paired with one or more obesity-related comorbidities.
    Comorbidity requirementAt least one obesity-related comorbidity is required when BMI is 35–39.
    Clinically significant weight regain
    ThresholdWeight regain equal to or greater than 50% of the weight previously lost.
    Reference weightThe calculation uses the member’s documented baseline weight.
    Measurement timing

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Initial Authorization: Six-Month Approval

    Submit for initial authorization when the member meets all eligibility and medical-necessity requirements. Approval may be granted for six months when the medication is prescribed for chronic weight management and the member participates in a provider-supervised comprehensive weight-management program.

    • Coverage must include treatment of Class III or severe obesity: BMI >= 40, or BMI 35–39 with one or more obesity-related comorbidities.
    • Apply the member’s Evidence of Coverage, applicable California law, FDA-approved labeling, and generally accepted standards of care.
    Prior Authorization

    Continuation Authorization: Additional Six Months

    Request continuation authorization for an additional six months only when ongoing clinical criteria are documented, including continued medical necessity, medication adherence, tolerance, and participation in the comprehensive weight-management program.

    • Document continued weight loss or maintenance of previously achieved weight without clinically significant weight regain.

    Policy Scope and Clinical Context

    This policy addresses FDA-approved anti-obesity medications used for chronic weight management in members with severe or Class III obesity. Medication therapy is intended to be provided as part of a comprehensive, provider-supervised weight management program that includes nutritional counseling, physical activity, behavioral modification, and periodic clinical follow-up. Continued treatment depends on ongoing clinical benefit, tolerability, adherence, and participation in that program.

    Key Policy Definitions

    Anti-Obesity Medication
    Medication typePrescription medication.
    Approval authorityApproved by the U.S. Food and Drug Administration (FDA).
    PurposeApproved for chronic weight management.
    Clinical Benefit
    DefinitionDocumented improvement attributable to anti-obesity medication.
    Weight outcomesMay be demonstrated by continued weight loss or maintenance of previously achieved weight loss.
    Medical-condition outcomeMay be demonstrated by improvement or stabilization of obesity-related medical conditions.
    Policy Summary
    PayerVentura County Health Care Plan
    PolicyGLP-1 Medications for Weight Loss Policy
    Policy CodePolicy 066
    Change TypeNew policy replacing the prior Weight Reduction Medications and Programs policy
    Effective DateDecember 20, 2026
    Next Review DateN/A
    Key ActionBefore requesting Zepbound, document that the member has tried Wegovy injection or Wegovy tablets and meets applicable prior-authorization criteria.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaClinical Thresholds and Review TriggersAuthorization, Documentation, and Denial RisksPolicy Scope and Clinical ContextKey Policy Definitions
    Documentation demonstrates continued weight loss since the previous authorization period.
  1. Documentation demonstrates maintenance of weight loss previously achieved without clinically significant weight regain.
  2. A completed Prescription Drug Prior Authorization Request Form for Weight Loss Medication is submitted, including the member's weight and height measurements obtained and documented by a healthcare professional during an in-person physical examination.
  3. Weight Watchers, Jenny Craig, Diet Center, or similar programs.
  4. Whole body calorimetry (diagnostic study).
  5. Other devices, products, and services related to weight loss.
  6. Measured at the time of the continuation authorization request.
    BMI
    Current documented BMI18.5 kg/m² or less.
    Review requirementThe request is referred to an MD reviewer for clinical review.
    Applicable requestsThe limitation applies when the patient’s current documented BMI is 18.5 kg/m² or less.
    Zepbound patient age
    Age thresholdYounger than 18 years.
    MedicationZepbound.
    Review requirementThe request is referred to an MD reviewer for clinical review.
  7. Confirm that the medication remains well tolerated and that the member demonstrates medication adherence.
  8. Prior Authorization

    Product Prior Authorization Required

    All products remain subject to applicable benefit coverage and prior-authorization requirements. Apply the policy’s product-specific requirements before submitting or approving a request.

    • Wegovy injection and Wegovy tablets are Step 1 products.
    • Zepbound injection is a Step 2 product.
    • Foundayo tablets and Saxenda injection are not subject to the Step Therapy sequence but remain subject to applicable prior-authorization criteria.
    Note

    MD Clinical Review Limitations

    Requests that cannot be automatically adjudicated under the established criteria require review by an MD reviewer. This includes low current documented BMI, certain Zepbound age requests, and unusual or otherwise out-of-criteria circumstances.

    • Refer requests with a current documented BMI of <= 18.5 kg/m² to an MD reviewer.
    • Refer Zepbound requests for patients younger than 18 years of age to an MD reviewer.
    • Refer requests outside established coverage criteria or involving unusual clinical circumstances to an MD reviewer.
    Step Therapy

    Step 1 Required Before Zepbound

    Before approving a Step 2 product for chronic weight management, verify that the required Step 1 product sequence has been completed and that all applicable prior-authorization criteria are met.

    • Step 1 products: Wegovy (semaglutide) injection or Wegovy (semaglutide) tablets.
    • Step 2 product: Zepbound (tirzepatide) injection.
    • Foundayo and Saxenda are evaluated under applicable prior-authorization criteria and are outside the Step Therapy sequence.
    Step Therapy

    Zepbound Step Requirement

    Approve Zepbound only when the member has tried Wegovy injection or Wegovy tablets and meets the applicable prior-authorization criteria. A prior trial of Foundayo or Saxenda does not satisfy the Step 1 requirement unless an applicable Step Therapy exception is met.

    • Document the prior Wegovy injection or tablet trial.
    • Do not count a Foundayo or Saxenda trial as completion of Step 1 absent an applicable exception.

    Unsupported block type: documentation

    Documentation Required

    Initial Medical-Necessity Documentation

    For initial authorization, document that the member meets the policy’s eligibility and medical-necessity requirements for chronic obesity treatment and is receiving medication as part of a comprehensive weight-management program.

    • Document current BMI: BMI >= 40, or BMI 35–39 with at least one obesity-related comorbidity.
    • Document the chronic weight-management indication.
    • Document participation in a provider-supervised comprehensive weight-management program.
    • Include the completed prior-authorization form with in-person, professionally obtained height and weight measurements.
    Documentation Required

    Continuation Documentation

    For continuation authorization, document ongoing medical necessity and the member’s continued clinical response, tolerance, adherence, and participation in the comprehensive weight-management program.

    • Document continued weight loss or maintenance of previously achieved weight without clinically significant weight regain.
    • Document that the medication remains well tolerated.
    • Document medication adherence and continued program participation.
    • Resubmit the required prior-authorization form with current height and weight measurements obtained during an in-person physical examination.
    Documentation Required

    Current Documented BMI

    Use the member’s current documented BMI when evaluating the request. A BMI of 18.5 kg/m² or less triggers referral to an MD reviewer for clinical review.

    • Ensure current height and weight are documented by a healthcare professional during an in-person physical examination.
    • Refer current documented BMI <= 18.5 kg/m² for MD clinical review rather than automatic adjudication.
    Denial Risk

    Medical Necessity or Step-Therapy Failure

    Deny or do not approve requests when the member does not meet the policy’s medical-necessity criteria or when a required Step Therapy sequence has not been satisfied.

    • Medical necessity requires treatment of Class III or severe obesity and the applicable chronic weight-management criteria.
    • Zepbound requires a prior trial of Wegovy injection or Wegovy tablets unless an applicable Step Therapy exception is met.
    • Foundayo or Saxenda use alone does not satisfy the Zepbound Step 1 requirement.
    Denial Risk

    Non-Covered Uses

    Do not approve anti-obesity medications when prescribed solely for excluded uses or when the member otherwise fails medical-necessity requirements.

    • Cosmetic weight loss.
    • Appearance enhancement.
    • Athletic performance.
    • Member does not satisfy medical-necessity criteria.
    • Any indication excluded under the member’s Evidence of Coverage.
    Denial Risk

    Failure of Continuation Criteria

    Deny continuation when the member no longer satisfies continuation criteria or the record does not demonstrate an ongoing therapeutic benefit. Therapeutic failure includes failure to demonstrate continued clinical benefit despite appropriate therapy, medication adherence, and participation in a comprehensive weight-management program.

    • Continued medical necessity is not demonstrated.
    • Medication is not well tolerated or medication adherence is not demonstrated.
    • The member no longer participates in the comprehensive weight-management program.
    • There is no continued weight loss or maintenance of achieved weight, or there is clinically significant weight regain.
    Denial Risk

    Non-Covered Medication Uses

    Do not approve anti-obesity medication requests for excluded indications, including cosmetic, appearance-related, athletic-performance, or other uses that do not satisfy medical necessity or the member’s Evidence of Coverage.

    • Apply the non-covered-use exclusions before authorization.
    • Refer unusual circumstances outside established criteria for MD review when appropriate.
    Denial Risk

    Non-Covered Weight-Reduction Services

    Do not submit weight-reduction services or supplies that are expressly excluded under the policy; they are not covered benefits for weight reduction.

    • Rice or other special-diet supplements or substitutes, including amino acid supplements, Optifast liquid protein meals, and NutriSystem pre-packaged foods.
    • Human chorionic gonadotropin (HCG) or vitamin injections for weight loss.
    • Acupuncture for weight loss.
    • Hospital confinements for a weight-reduction program.
    • Exercise programs or use of exercise equipment.
    • Weight Watchers, Jenny Craig, Diet Center, or similar programs.
    • Whole-body calorimetry (diagnostic study).
    • Other devices, products, and services related to weight loss.
    Clinically Significant Weight Regain
    Regain thresholdEqual to or greater than 50% of the weight previously lost.
    BaselineCalculated from the member’s documented baseline weight.
    Assessment pointMeasured at the time of the continuation authorization request.
    Comprehensive Weight Management Program
    SupervisionProvider-supervised treatment plan.
    Lifestyle componentsIncludes nutritional counseling, physical activity, and behavioral modification.
    Follow-upIncludes periodic clinical follow-up.
    Continued Medical Necessity
    Clinical statusDocumentation demonstrates continued clinical benefit and that the medication remains clinically appropriate.
    Treatment experienceThe medication is well tolerated and the member remains adherent.
    Program and outlookThe member continues participating in a comprehensive weight management program and continuation is expected to provide ongoing therapeutic benefit.
    Maintenance of Weight Loss
    Weight outcomeMaintenance of previously achieved therapeutic weight reduction.
    Regain requirementWithout clinically significant weight regain.
    Use in continuation reviewSupports continued treatment when therapeutic weight reduction is maintained without clinically significant regain.
    Medication Adherence
    DefinitionMedication is taken as prescribed.
    Medication useThe member follows the prescribed medication regimen.
    Continuation relevanceAdherence is an element of continued medical necessity.
    Obesity-Related Comorbidity
    DefinitionA medical condition associated with obesity.
    ExamplesType 2 diabetes, hypertension, dyslipidemia, and obstructive sleep apnea.
    Additional examplesCoronary artery disease and obesity hypoventilation syndrome.
    Therapeutic Failure
    DefinitionFailure to demonstrate continued clinical benefit.
    Therapy conditionOccurs despite appropriate therapy.
    Participation and adherence conditionOccurs despite medication adherence and participation in a comprehensive weight management program.